Haemophilia A gene therapy

Haemophilia

Volumn 4, Issue 4, 1998, Pages 380-388

  Connelly, S ^a   Kaleko, M ^a  

^a NOVARTIS PHARMA AG   (Switzerland)

Author keywords

Factor VIII; Gene therapy; Haemophilia A; Viral vectors

Indexed keywords

BLOOD CLOTTING FACTOR; BLOOD CLOTTING FACTOR 8;

ANIMAL EXPERIMENT; ANIMAL MODEL; CONFERENCE PAPER; DOG; EXPRESSION VECTOR; GENE EXPRESSION; GENE THERAPY; HEMOPHILIA A; MONKEY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROPHYLAXIS;

EID: 0031828432     PISSN: 13518216     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2516.1998.440380.x     Document Type: Conference Paper

References (97)

1. Sadler JE, Davie EW, Nienhuis AW, Leder P, Majerus PW, eds. The Molecular Basis of Blood Diseases. New York: W.B. Saunders, 1987; 575-98.
2. Antonarakis SE, Kazazian HH, Tuddenham EGD. Molecular etiology of factor VIII deficiency in hemophilia A. Human Mutation 1995; 5: 1-22.
3. DiMichele D. Hemophilia 1996. New approach to an old disease. Pediatr Clin North Am 1996; 43: 709-36.
4. White GC, Roberts HR. The treatment of factor VIII inhibitors - a general overview. Vox Sang 1996; 70 (Suppl 1): 19-23.
5. Lozier JN, Brinkhous KM. Gene therapy and the hemophilias. JAMA 1994; 271: 47-51.
6. Fallaux FJ, Hoeben RC, Briet E. State and prospects of gene therapy for the hemophilias. Thromb Haemost 1995; 74: 263-73.
7. Hoeben RC. Gene therapy for the haemophilias: Current status. Biological 1995; 23: 27-9.
8. Smith TAG. Gene therapy for haemophilia. Exp Opin Invest Drugs 1995; 4: 833-42.
9. Connelly S, Kaleko M. Gene therapy for hemophilia A. Thromb Haemost 1997; 78: 31-6.
10. Smith TAG. Gene therapy for haemophilia. Exp Opin Invest Drugs 1997; 6: 1685-90.
11. Wood WI, Capon DJ, Simonsen CC, Eaton DL, Gitschier J, Keyt B, et al. Expression of active human factor VIII from recombinant DNA cloned. Nature 1984; 312: 330-7.
12. Toole JJ, Knopf JL, Wozney JM, Sultzman PA, Buecker J, Pittman DD, et al. Molecular cloning of a cDNA encoding antihemophiliac factor. Nature 1984; 312: 342-6.
13. Kaufman RJ. Biological regulation of factor VIII activity. Annu Rev Med 1992; 43: 325-39.
14. Vehar GA, Lawn RM, Tuddenham EGD, Albertini A, Lenfant CL, Mannucci PM, Sixma JJ, eds. Biotechnology of plasma proteins, Curr Stud Hematol Blood Transf. Basel: Karger, 1991; 2155-70.
15. Hoyer LW. Hemophilia A. N Engl J Med 1994; 330: 38-47.
16. Eaton DL, Wood WI, Eaton D, Hass PE, Hollingshead P, Wion K, et al. Construction and characterization of an active factor VIII variant lacking the central one-third of the molecule. Biochem 1986; 25: 1-2.
17. Toole JJ, Pittman DD, Orr EC, Murtha P, Wasley LC, Kaufman RJ. A large region (∼95 kDa) of human factor VIII is dispensable for in vitro procoagulant activity. Proc Natl Acad Sci USA 1986; 83: 5939-42.
18. Pittman DD, Alderman EM, Tomkinson KN, Wang JH, Giles AR, Kaufman RJ. Biochemical, Immunological, and in vivo functional characterization of B-domain-deleted factor VIII. Blood 1993; 81: 2925-35.
19. Brinster RL, Allen JM, Behringer RR, Gelinas RE, Palmiter RD. Introns increase transcriptional efficiency in transgenic mice. Proc Natl Acad Sci USA 1988; 85: 836-40.
20. Lynch CM, Israel DI, Kaufman RJ, Miller AD. Sequences in the coding region of clotting factor VIII act as dominant inhibitors of RNA accumulation and protein production. Hum Gene Ther 1993; 4: 259-72.
21. Hoeben RC, Fallaux FJ, Cramer SJ, van den Wollenberg JM, Van Ormondt H, Briet E, Van Der Eb AJ. Expression of the blood-clotting factor-VIII cDNA is repressed by a transcriptional silencer located in its coding region. Blood 1995; 85: 2447-54.
22. Koeberl DD, Haibert CL, Krumm A, Miller AD. Sequences within the coding regions of clotting factor VIII and CFTR block transcriptional elongation. Hum Gene Ther 1995; 6: 469-79.
23. Kaufman RJ, Wasley LC, Dorner AJ. Synthesis, processing, and secretion of recombinant human factor VIII expressed in mammalian cells. J Biol Chem 1988; 263: 6352-62.
24. Dwarki VJ, Belloni P, Nijjar T, Smith J, Couto L, Rabier M, et al. Gene therapy for hemophilia A: Production of therapeutic levels of human factor VIII in vivo in mice. Proc Natl Acad Sci USA 1995; 92: 1023-7.
25. Miller DG, Adam MA, Miller AD. Gene transfer by retrovirus vectors occurs only in cells that are actively replicating at the time of infection. Mol Cell Biol 1990; 10: 4239-42.
26. Israel DI, Kaufman RJ. Retroviral-mediated transfer and amplification of a functional human factor VIII gene. Blood 1990; 75: 1074-80.
27. Hoeben RC, van der Jagt RC, Schoute F, Van Tilburg NH, Verbeet MP, Briet E, et al. Expression of functional factor VIII in primary human skin fibroblasts after retrovirus-mediated gene transfer. J Biol Chem 1990; 265: 7318-23.
28. Hoeben RC, Einerhand MP, Briet E, Van Ormondt H, Valerio D, Van Der Eb AJ. Toward gene therapy in haemophilia A: retrovirus-mediated transfer of a factor VIII gene into murine haematopoietic progenitor cells. Thromb Haemost 1992; 67: 341-5.
29. Hoeben RC, Fallaux FJ, Van Tilburg NH, Cramer SJ, Van Ormondt H, Briet E, Van Der Eb AJ. Toward gene therapy for hemophilia A: long-term persistence of factor VIII-secreting fibroblasts after transplantation into immunodeficient mice. Hum Gene Ther 1993; 4: 179-86.
30. Chuah MKL, Vandendriessche T, Morgan RA. Development and analysis of retroviral vectors expressing human factor VIII as a potential gene therapy for hemophilia A. Hum Gene Ther 1995; 6: 1363-77.
31. Krall WJ, Skelton DC, Yu X, Riviere I, Lehn P, Mulligan RC, Kohn DB. Increased levels of spliced RNA account for augmented expression from the MFG retroviral vector in hematopoietic cells Gene Ther 1996; 3: 37-48.
32. Zatloukal K, Cotten M, Berger M, Schmidt W, Wagner E, Birnstiel ML. In vivo production of human factor VIII in mice after intrasplenic implantation of primary fibroblasts transfected by receptor-mediated, adenovirus-augmented gene delivery. Proc Natl Acad Sci USA 1994; 91: 5148-52.
33. Berkner KL. Development of adenovirus vectors for the expression of heterologous genes. Biotechniques 1988; 6: 616-29.
34. Trapnell BC, Gorziglia M. Gene therapy using adenoviral vectors. Curr Opin Biotechnol 1994; 5: 617-25.
35. Ginsberg HS. The Adenoviruses. New York-London: Plenum Press, 1984.
36. Horwitz MS, Fields BN, Knipe DM, eds. Virology. New York: Raven Press, 1990; 1679-721.
37. Connelly S, Smith TAG, Dhir G, Gardner JM, Mehaffey MG, et al. In vivo gene delivery and expression of physiological levels of functional human factor VIII in mice. Hum Gene Ther 1995; 6: 185-93.
38. Connelly S, Gardner JM, Lyons RM, McClelland A, Kaleko M. Sustained expression of therapeutic levels of human factor VIII in mice. Blood 1996; 87: 4671-7.
39. Connelly S, Gardner JM, McClelland A, Kaleko M. High level tissue-specific expression of functional human FVIII in mice. Hum Gene Ther 1996; 7: 183-95.
40. Connelly S, Mount J, Mauser A, Gardner JM, Kaleko M, McClelland A, Lothrop CD. Complete short-term correction of canine hemophilia A by in vivo gene therapy. Blood 1996; 88: 3846-53.
41. Connelly S, Andrews J, Gallo AM, Qian J, Hoyer L, Kadan MJ, et al. Sustained phenotypic correction of murine hemophilia A by in vivo gene therapy. Blood 1998; in press.
42. Smith TAG, Mehaffey MG, Kayda DB, Saunders JM, Yei S, Trapnell BC, et al. Adenovirus-mediated expression of therapeutic plasma levels of human factor IX in mice. Nat Genet 1993; 5: 397-402.
43. Kozarsky KF, Wilson JM. Gene therapy: adenovirus vectors. Curr Opin Genet Dev 1993; 3: 499-503.
44. Smith TAG, Brann T, Kayda DB, Shoemaker A, Roy S, Shirley P, et al. Adenoviral vector-mediated expression of physiological levels of human factor VIII in non-human primates. In preparation.
45. Swanson ME, Hughes TE, St. Denny I, France DS, Paterniti JR, Tapparelli C, et al. High level expression of human apolipoprotein A-1 in transgenic rats raises total serum high density lipoprotein cholesterol and lowers rat apolipoprotein A-1. Transgenic Res 1992; 1: 142-7.
46. Morral N, O'Neal W, Zhou H, Langston C, Beaudet A. Immune responses to reporter proteins and high viral dose limit duration of expression with adenoviral vectors: comparison of E2a wild type and E2a deleted vectors. Hum Gene Ther 1997; 8: 1275-86.
47. Bi L, Lawler AM, Antonarakis SE, High KA, Gerhart JD, Kazazian HH. Targeted disruption of the mouse factor VIII gene produces a model of haemophilia A. Nature Genetics 1995; 10: 119-21.
48. Qian J, Bi L, Kazazian HH, et al. Inhibitor development and T cell response to human factor VIII in murine hemophilia A. [Abstract] Blood 1996; 88 (Suppl): 656a.
49. Tinlin S, Webster S, Giles AR. The development of homologous (canine/anti-canine) antibodies in dogs with haemophilia A (factor VIII deficiency): A ten-year longitudinal study. Thromb Haemost 1993; 69: 21-4.
50. Cameron C, Notley C, Hoyle S, McGlynn L, Hough C, Kamisue S, et al. The canine factor VIII CDNA and 5′ flanking sequence. Thromb Haemost; in press.
51. Roy S, Shirley P, Connelly S, Andrews JL, Gardner JM, McClelland A, Kaleko M. Construction and evaluation in mice of a novel epitope tagged factor VIII adenovirus vector. In preparation.
52. Andrews JL, Weaver L, McClelland A, Kaleko M, Connelly S. Efficient adenoviral vector transduction and expression of functional human factor VIII in cultured primary human hepatocytes. In preparation.
53. Dorner AJ, Bole DG, Kaufman RJ. The relationship of N-Iinked glycosylation and heavy chain-binding protein association with the secretion of glycoproteins. J Cell Biol 1987; 105: 2665-74.
54. Yang Y, Nunes FA, Berencsi K, Furth EE, Gönczöl E, Wilson JM. Cellular immunity to viral antigens limits E1-deleted adenoviruses for gene therapy. Proc Natl Acad Sci USA 1994; 91: 4407-11.
55. Yang Y, Ertl HCJ, Wilson JM. MHC class I-restricted cytotoxic T lymphocytes to viral antigens destroy hepatocytes in mice infected with El-deleted recombinant adenoviruses. Immun 1994; 1: 433-42.
56. Hardy S, Kitamura M, Harris-Stansil T, Dai Y, Phipps ML. Construction of adenovirus vectors through Cre-lox recombination. J Virol 1997; 71: 1842-9.
57. Kumar-Singh R, Chamberlain JS. Encapsidated adenovirus minichromosomes allow delivery and expression of a 14 kb dystrophin CDNA to muscle cells. Hum Mol Genet 1996; 5: 913-21.
58. Zhou H, O'Neal W, Morral N, Beaudet AL. Development of a complementing cell line and a system for construction of adenovirus vectors with E1 and E2a deleted. J Virol 1996; 70: 7030-8.
59. Wang Q, Jia X, Finer MH. A packaging cell line for propagation of recombinant adenovirus vectors containing two lethal gene-region deletions. Gene Therapy 1995; 2: 775-83.
60. Yeh P, Dedieu JF, Orsini C, Vigne E, Denefle P, Perricaudet M. Efficient dual transcomplementation of adenovirus E1 and E4 regions from a 293-derived cell line expressing a minimal E4 functional unit. J Virol 1996; 70: 559-65.
61. Gao G, Yang Y, Wilson JM. Biology of adenovirus vectors with E1 and E4 deletions for liver-directed gene therapy. J Virol 1996; 70: 8934-43.
62. Gorziglia MI, Kadan MJ, Yei S, Lim J, Lee GM, Luthra R, Trapnell BC. Elimination of both E1 and E2a from adenovirus vectors further improves prospects for in vivo human gene therapy. J Virol 1996; 6: 4173-8.
63. Kochanek S, Clemens PR, Mitani K, Chen H, Chan S, Caskey CT. A new adenoviral vector: replacement of all viral coding sequences with 28 kb of DNA independently expressing both full-length dystrophin and beta-galactosidase. Proc Natl Acad Sci USA 1996; 93: 5731-6.
64. Clemens PR, Kochanek S, Sunada Y, Chan S, Chen H, Campbell KP, Caskey CT. In vivo muscle gene transfer of full-length dystrophin with an adenoviral vector that lacks all viral genes. Gene Therapy 1996; 3: 965-72.
65. Lieber A, He C, Kirillova I, Kay MA. Recombinant adenoviruses with large deletions generated by cre-mediated excision exhibit different biological properties compared with first-generation vectors in vitro and in vivo. J Virol 1996; 70: 8944-60.
66. Fisher KJ, Choi H, Bruda J, Chen S, Wilson JM. Recombinant adenovirus deleted of all viral genes for gene therapy of cystic fibrosis. Virology 1996; 217: 11-22.
67. Haecker SE, Stedman HH, Balice-Gordon RJ, Smith DBJ, Greelish JP, Mitchell MA, et al. In vivo expression of full-length human dystrophin from adenoviral vectors deleted of all viral genes. Hum Gene Ther 1996; 7: 1907-14.
68. Roy S, Shirley PS, McClelland A, Kaleko M. Circumvention of immunity to the adenovirus major coat protein hexon. J Virol; in preparation.
69. Smith TAG, White BD, Gardner JM, Kaleko M, McClelland A. Transient immunosuppression permits successful repetitive intravenous administration of an adenovirus vector. Gene Therapy 1996; 3: 496-502.
70. Yang Y, Trinchicri G, Wilson JM. Recombinant IL-12 prevents formation of blocking IgA antibodies to recombinant adenovirus and allows repeated gene therapy to mouse lung. Nature Med 1995; 1: 890-3.
71. Yang Y, Greenough K, Wilson JM. Transient immune blockade prevents formation of neutralizing antibody to recombinant adenovirus and allows repeated gene transfer to mouse liver. Gene Therapy 1996; 5: 412-20.
72. Kotin RM. Prospects for the use of adeno-associated virus as a vector for human gene therapy. Hum Gene Ther 1994; 5: 793-801.
73. Carter BJ. The promise of adeno-associated virus vectors. Nature Biotechnology 1996; 14: 1725-6.
74. Xiao X, Li J, Samulski RJ. Efficient long-term gene transfer into muscle tissue of immunocompetent mice by adeno-associated virus vector. J Virol 1996; 70: 8098-108.
75. Herzog RW, Hagstrom JN, Kung SH, Tai SJ, Wilson JM, Fisher KJ, High KA. Stable gene transfer and expression of human blood coagulation factor IX after intramuscular injection of recombinant adeno-associated virus. Proc Natl Acad Sci USA 1997; 94: 5804-9.
76. Fisher KJ, Jooss K, Alston J, Yang Y, Haecker SE, High K, et al. Recombinant adeno-associated virus for muscle directed gene therapy. Nat Med 1997; 3: 306-12.
77. McCown TJ, Xiao X, Li J, Breese GR, Samulski RJ. Differential and persistent expression patterns of CNS gene transfer by an adeno-associated virus (AAV) vector. Brain Res 1996; 713: 99-107.
78. Halbert CL, Standaert TA, Aitken ML, Alexander IE, Russell DW, Miller AD. Transduction by adeno-associated virus vectors in the rabbit airway: efficiency, persistence, and readministration. J Virol 1997; 71: 5932-41.
79. Snyder RO, Miao CH, Patijn GA, Spratt SK, Danos O, Nagy D, et al. Persistent and therapeutic concentrations of human factor IX in mice after hepatic gene transfer of recombinant AAV vectors. Nat Genet 1997; 16: 270-6.
80. Koeberl DD, Alexander IE, Halbert CL, Russell DW, Miller AD. Persistent expression of human clotting factor IX from mouse liver after intravenous injection of adeno-associated virus vectors. Proc Natl Acad Sci USA 1997; 94: 1426-31.
81. Gnatenki D, Hearing P, Gergel J, et al. Generation and characterization of recombinant adeno-associated viral (RAAV) vectors for factor VIII gene therapy. [Abstract] Blood 1996; 88: 139.
82. Bosch A, McCray PB, Chang SMW, Ulich TR, Simonet WS, Jolly DJ, Davidson BL. Proliferation induced by keratinocyte growth factor enhances in vivo retroviralmediated gene transfer to mouse hepatocytes. J Clin Invest 1996; 98: 2683-7.
83. Greengard JS, Bodner M, McCormack J, Edwards WR, Sesintaffar JL, Hsu D, et al. Sustained high level factor VIII expression in immunocompetent rabbits and dogs following peripheral intravenous injection of retroviral vector. International Symposium on Gene Therapy for Hemophilia, 1997; Abstract.
84. Naldini L, Blomer U, Gage FH, Trono D, Verma IM. Efficient transfer, integration, and sustained long-term expression of the transgene in adult rat brains injected with a lentiviral vector. Proc Natl Acad Sci USA 1996; 93: 11382-8.
85. Naldini L, Blomer U, Gallay P, Ory D, Mulligan R, Gage FH, et al. In vivo gene delivery and stable transduction of nondividing cells by a lentiviral vector. Science 1996; 272: 263-7.
86. Blomer U, Naldini L, Kafri T, Trono D, Verma IM, Gage FH. Highly efficient and sustained gene transfer in adult neurons with a lentiviral vector. J Virol 1997; 71: 6641-9.
87. Kafri T, Blomer U, Peterson DA, Gage FH, Verma IM. Sustained expression of genes delivered directly into liver and muscle by lentiviral vectors. Nature Genetics 1997; 17: 314-7.
88. Naldini L, Song J, Kelly M, Davis J, Nagy D, Mandel R, et al. Lentiviral vectors for in vivo gene delivery. International Symposium on Gene Therapyfor Hemophilia, 1997; abstract.
89. Zufferey R, Nagy D, Mandel RJ, Naldini L, Trono D. Multiply attenuated lentiviral vector achieves efficient gene delivery in vivo. Nature Biotechnology 1997; 15: 871-5.
90. Corbeau P, Kraus G, Wong-Stall F. Efficient gene transfer by a human immunodeficiency virus type I (HIV-1)-derived vector utilizing a stable HIV packaging cell line. Proc Natl Acad Sci USA 1996; 93: 14070-5.
91. Fisher KJ, Kelley WM, Burda JF, Wilson JM. A novel adenovirus-adeno-associated virus hybrid vector that displays efficient rescue and delivery of the AAV genome. Hum Gene Ther 1996; 7: 2079-87.
92. Wang S, Vos JM. A hybrid herpesvirus infectious vector based on Epstein-Barr virus and herpes simplex virus type I for gene transfer into human cells in vitro and in vivo. J Virol 1996; 70: 8422-30.
93. Johnston KM, Jacoby D, Pechan PA, Fraefel C, Borghesani P, Schuback D, et al. HSV/AAV hybrid amplicon vectors extend transgene expression in human glioma cells. Hum Gene Ther 1997; 8: 359-70.
94. Feng M, Jackson WH, Goldman CK, Rancourt C, Wang M, Dusing SK, Slegal G, Curiel DT. Stable in vivo gene transduction via a novel adenoviral/retroviral chimeric vector. Nature Biotechnology 1997; 15: 866-70.
95. Wu GY, Wu CH. Receptor-mediated gene delivery and expression in vivo. J Biol Chem 1988; 263: 14621-4.
96. Perales JC, Ferkol T, Beegen H, Ratnoff OD, Hanson RW. Gene transfer in vivo: Sustained expression and regulation of genes introduced into the liver by receptor-targeted uptake. Proc Natl Acad Sci USA 1994; 91: 4086-90.
97. Ill CR, Yang CO, Bidlingmaier SM, et al. Engineering the human factor VIII CDNA for targeted gene therapy. [Abstract] Thromb Haemost 1997; Suppl: 3.